Browsing NTNU Open by Author "Tekpli, Xavier"

Now showing items 1-3 of 3

    • Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells 

      Tekpli, Xavier; Urbanucci, Alfonso; Hashim, Adnan; Vågbø, Cathrine Broberg; Lyle, Robert; Kringen, Marianne K.; Staff, Anne Cathrine; Dybedal, Ingunn; Mills, Ian Geoffrey; Klungland, Arne; Staerk, Judith (Journal article; Peer reviewed, 2016)
      Background Hematopoietic stem cell renewal and differentiation are regulated through epigenetic processes. The conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC) by ten-eleven-translocation enzymes provides ...

    • Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer 

      Gythfeldt, Hedda von der Lippe; Lien, Tonje Gulbrandsen; Tekpli, Xavier; Silwal-Pandit, Laxmi; Borgen, Elin; Garred, Øystein; Skjerven, Helle; Schlichting, Ellen; Lundgren, Steinar; Wist, Erik; Naume, Bjørn; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Lingjærde, Ole Christian; Engebråten, Olav (Peer reviewed; Journal article, 2020)
      Antiangiogenic drugs are potentially a useful supplement to neoadjuvant chemotherapy for a subgroup of patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, but reliable biomarkers for ...

    • Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers 

      Nome, Marianne Eikhom; Euceda, Leslie R.; Jabeen, Shakila; Debik, Julia; Bathen, Tone Frost; Giskeødegård, Guro F.; Tasken, Kristin Austlid; Mælandsmo, Gunhild Mari; Halvorsen, Bente; Yndestad, Arne; Borgen, Elin; Garred, Øystein; Aukrust, Pål; Ueland, Thor; Engebraaten, Olav; Kristensen, Vessela N.; Tekpli, Xavier (Journal article; Peer reviewed, 2019)
      Angiogenesis is necessary for tumor growth and has been targeted in breast cancer; however, it is unclear which patients will respond and benefit from antiangiogenic therapy. We report noninvasive monitoring of patient ...